MX2007001940A - 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolidin-2,4-diona y analogos como inhibidores de macrofago elastasa. - Google Patents
5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolidin-2,4-diona y analogos como inhibidores de macrofago elastasa.Info
- Publication number
- MX2007001940A MX2007001940A MX2007001940A MX2007001940A MX2007001940A MX 2007001940 A MX2007001940 A MX 2007001940A MX 2007001940 A MX2007001940 A MX 2007001940A MX 2007001940 A MX2007001940 A MX 2007001940A MX 2007001940 A MX2007001940 A MX 2007001940A
- Authority
- MX
- Mexico
- Prior art keywords
- benzyloxyphenylthio
- imidazolidin
- fur
- dione
- inhibitors
- Prior art date
Links
- ZUOUZWHAINARGI-UHFFFAOYSA-N 5-[3-(4-phenylmethoxyphenyl)sulfanylfuran-2-yl]imidazolidine-2,4-dione Chemical compound O=C1NC(=O)NC1C1=C(SC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C=CO1 ZUOUZWHAINARGI-UHFFFAOYSA-N 0.000 title abstract 2
- 108030001712 Macrophage elastases Proteins 0.000 title abstract 2
- 102100027998 Macrophage metalloelastase Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60273604P | 2004-08-19 | 2004-08-19 | |
| PCT/US2005/029259 WO2006023562A2 (en) | 2004-08-19 | 2005-08-17 | 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007001940A true MX2007001940A (es) | 2007-07-24 |
Family
ID=35968136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007001940A MX2007001940A (es) | 2004-08-19 | 2005-08-17 | 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolidin-2,4-diona y analogos como inhibidores de macrofago elastasa. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7179831B2 (https=) |
| EP (1) | EP1789036B1 (https=) |
| JP (1) | JP5042833B2 (https=) |
| KR (1) | KR101197325B1 (https=) |
| CN (1) | CN101014338B (https=) |
| AT (1) | ATE508744T1 (https=) |
| AU (1) | AU2005277432B2 (https=) |
| BR (1) | BRPI0514470B8 (https=) |
| CA (1) | CA2577430C (https=) |
| DK (1) | DK1789036T3 (https=) |
| ES (1) | ES2364068T3 (https=) |
| MX (1) | MX2007001940A (https=) |
| NZ (1) | NZ553258A (https=) |
| RU (1) | RU2391339C2 (https=) |
| SI (1) | SI1789036T1 (https=) |
| WO (1) | WO2006023562A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007084485A2 (en) * | 2006-01-13 | 2007-07-26 | Battelle Memorial Institute | Markers for assessing copd-related diseases |
| EP2907512A1 (en) | 2014-02-14 | 2015-08-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Inhibitors of MMP-12 as antiviral Agents |
| MX387820B (es) * | 2016-08-19 | 2025-03-18 | Foresee Pharmaceuticals Co Ltd | Composición farmacéutica y métodos de usos. |
| US10532102B2 (en) * | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| JP6934012B2 (ja) * | 2016-09-23 | 2021-09-08 | 科研製薬株式会社 | （ｒ）‐５‐（３，４‐ジフルオロフェニル）‐５‐［（３‐メチル‐２‐オキソピリジン‐１（２ｈ）‐イル）メチル］イミダゾリジン‐２，４‐ジオンの製造方法およびその製造のための中間体 |
| SI3793995T1 (sl) | 2018-05-15 | 2024-05-31 | Foresee Pharmaceuticals Usa, Inc. | Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe |
| CA3158234A1 (en) * | 2019-11-14 | 2021-05-20 | Foresee Pharmaceuticals Co., Ltd. | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
| EP4351566A4 (en) * | 2021-06-08 | 2025-04-23 | Foresee Pharmaceuticals USA, Inc. | SAFE ADMINISTRATION OF MMP-12 INHIBITOR |
| RU2766551C1 (ru) * | 2021-07-19 | 2022-03-15 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | 5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1150975A1 (en) | 1998-12-31 | 2001-11-07 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
| US6352976B1 (en) * | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
| RU2150469C1 (ru) * | 1999-06-01 | 2000-06-10 | Уфимский государственный нефтяной технический университет | Способ получения 2-(фурил-2)-1,3-имидазолидинов |
| EP1288199A4 (en) | 2000-04-28 | 2005-10-12 | Shionogi & Co | INHIBITORS OF MMP-12 |
| SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US6890915B2 (en) | 2001-05-25 | 2005-05-10 | Bristol-Myers Squibb Pharma Company | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| EP1394159A1 (fr) * | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
| AU2003282920A1 (en) * | 2002-10-04 | 2004-05-04 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
-
2005
- 2005-08-17 JP JP2007527975A patent/JP5042833B2/ja not_active Expired - Fee Related
- 2005-08-17 CA CA2577430A patent/CA2577430C/en not_active Expired - Fee Related
- 2005-08-17 NZ NZ553258A patent/NZ553258A/en not_active IP Right Cessation
- 2005-08-17 ES ES05786673T patent/ES2364068T3/es not_active Expired - Lifetime
- 2005-08-17 SI SI200531283T patent/SI1789036T1/sl unknown
- 2005-08-17 CN CN2005800285556A patent/CN101014338B/zh not_active Expired - Fee Related
- 2005-08-17 DK DK05786673.3T patent/DK1789036T3/da active
- 2005-08-17 AU AU2005277432A patent/AU2005277432B2/en not_active Ceased
- 2005-08-17 AT AT05786673T patent/ATE508744T1/de not_active IP Right Cessation
- 2005-08-17 WO PCT/US2005/029259 patent/WO2006023562A2/en not_active Ceased
- 2005-08-17 EP EP05786673A patent/EP1789036B1/en not_active Expired - Lifetime
- 2005-08-17 US US11/205,954 patent/US7179831B2/en not_active Expired - Lifetime
- 2005-08-17 MX MX2007001940A patent/MX2007001940A/es active IP Right Grant
- 2005-08-17 RU RU2007105822/04A patent/RU2391339C2/ru not_active IP Right Cessation
- 2005-08-17 KR KR1020077006294A patent/KR101197325B1/ko not_active Expired - Fee Related
- 2005-08-17 BR BRPI0514470A patent/BRPI0514470B8/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1789036A2 (en) | 2007-05-30 |
| ES2364068T3 (es) | 2011-08-24 |
| SI1789036T1 (sl) | 2011-09-30 |
| RU2391339C2 (ru) | 2010-06-10 |
| KR20070045330A (ko) | 2007-05-02 |
| DK1789036T3 (da) | 2011-06-27 |
| RU2007105822A (ru) | 2008-09-27 |
| CN101014338B (zh) | 2010-06-16 |
| WO2006023562A2 (en) | 2006-03-02 |
| WO2006023562A3 (en) | 2006-04-20 |
| WO2006023562B1 (en) | 2006-06-22 |
| US7179831B2 (en) | 2007-02-20 |
| AU2005277432A1 (en) | 2006-03-02 |
| AU2005277432B2 (en) | 2011-11-24 |
| NZ553258A (en) | 2011-02-25 |
| EP1789036B1 (en) | 2011-05-11 |
| US20060041000A1 (en) | 2006-02-23 |
| HK1107774A1 (en) | 2008-04-18 |
| KR101197325B1 (ko) | 2012-11-05 |
| EP1789036A4 (en) | 2008-08-27 |
| JP5042833B2 (ja) | 2012-10-03 |
| BRPI0514470A (pt) | 2008-06-10 |
| BRPI0514470B8 (pt) | 2021-07-20 |
| CA2577430A1 (en) | 2006-03-02 |
| JP2008510701A (ja) | 2008-04-10 |
| CA2577430C (en) | 2010-12-07 |
| CN101014338A (zh) | 2007-08-08 |
| ATE508744T1 (de) | 2011-05-15 |
| BRPI0514470B1 (pt) | 2021-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200735865A (en) | Compositions of an anticonvulsant and methods of using the same for reversing weight gain | |
| ATE452631T1 (de) | N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer | |
| IL176571A0 (en) | Substituted azole derivatives, compositions, and methods of use | |
| GEP20094785B (en) | Pyrrolopyrazoles, potent kinase inhibitors | |
| NO20081636L (no) | FAP - inhibitorer | |
| WO2007136592A3 (en) | 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents | |
| DE60313872D1 (de) | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen | |
| TW200621253A (en) | 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof | |
| IL188398A0 (en) | Thiazoles derivatives as ampk activator | |
| ATE493037T1 (de) | Mykotoxin reduzierende zusammensetzung | |
| WO2008005145A3 (en) | Controlling memory parameters | |
| WO2005087724A3 (en) | Sulphonylpyrroles as hdac inhibitors | |
| IL190730A0 (en) | Potassium channel inhibitors | |
| WO2006034093A3 (en) | 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors | |
| TW200715969A (en) | Fungicidal active-compound combination | |
| MX2007001940A (es) | 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolidin-2,4-diona y analogos como inhibidores de macrofago elastasa. | |
| UA98608C2 (en) | Benzofused five-membered heterocycles and use thereof | |
| WO2005105079A3 (en) | Novel imidazoles | |
| AU2003234925A1 (en) | TGF-Alpha EXPRESSION INHIBITORS | |
| MX2007002917A (es) | Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma. | |
| NL1027655A1 (nl) | N-Alkylpyrrolen als HMG-CoA-reductaseremmers. | |
| EP1767200A4 (en) | MEDIUM AGAINST SKIN AGING | |
| NO20061316L (no) | Imidazopyndinderivater som induserbare NO-syntaseinhibitorer | |
| WO2007089743A3 (en) | Potassium channel inhibitors | |
| ATE493390T1 (de) | 2,3-diaryl-pyrazolidine derivate als neurotensin abbauende enzyme-inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |